

STUDIENLISTE September 2019
Studien offen für Accrual
DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

fett = neu

Arzt/Ärztin

Zuständigkeit

Clinical Research
 Coordinator (CRC) /
 Stabssekretariat

LEUKÄMIE				
EKSG 15/193 2016-00548	SAKK GRAALL 2014	Multicenter trial for the treatment of Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)	M. Baumann Michael.Baumann@kssg.ch	S. Mayr/ J. Niedermann
2017-00372	SAKK CLL-13	SAKK CLL-13: A phase 3 multicenter, randomized, prospective, open-label trial of standard chemoimmunotherapy (FCR/BR) versus rituximab plus venetoclax (RvE) versus obinutuzumab (GA101) plus venetoclax (GvE) versus obinutuzumab plus ibrutinib plus venetoclax (GvE) in fit patients with previously untreated chronic lymphocytic leukemia (CLL) without del(17p) or TP53 mutation (GAIA Trial)	M. Baumann Michael.Baumann@kssg.ch	P. Caminada/ J. Niedermann
2016-01917	MDS – 14	Multicentre Observational Study of MDS Patients in Switzerland – Swiss MDS Registry	T. Silzle Tobias.silzle@kssg.ch	M. Steiner/ J. Niedermann
2018-00162	Blinicyto	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	M. Baumann Michael.Baumann@kssg.ch	A. Aeschbacher J. Niedermann
LYMPHOM				
2018-02243	EMN 17	A Phase 3 Study Comparing Daratumumab, VELCADE (bortezomib), Lenalidomide, and Dexamethasone (D-VRd) vs VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects with Previously Untreated Multiple Myeloma who are Eligible for High-dose Therapy	T. Silzle Tobias.silzle@kssg.ch	H. Nguyen/ J. Niedermann
EKSG 15/033	SAKK 36/13	Combination of ibrutinib and bortezomib followed by ibrutinib maintenance to treat patients with relapsed and refractory mantle cell lymphoma; a multicenter Phase I/II trial / Start Phase II am 18.11.16	M. Fehr Martin.fehr@kssg.ch	A. Harder/ J. Niedermann
EKSG 15/104	SAKK 35/14	Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy. A randomized, double-blinded, SAKK and NLG collaborative Phase II trial	F. Hitz Felicitas.hitz@kssg.ch	A. Harder/ J. Niedermann
2016-02186	SAKK HD 21	Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.	F. Hitz Felicitas.hitz@kssg.ch	P. Caminada/ J. Niedermann
2017-01342	SAKK TRIANGLE	TRIANGLE: autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing induction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial	F. Hitz Felicitas.hitz@kssg.ch	R. Demmer/ J. Niedermann
BASEC 2018-01769	IELSG 45	Randomized Phase II Trial on fitness and comorbidity-tailored treatment in elderly patients with newly diagnosed primary CNS Lymphoma (FIORELLA Trial)	F. Hitz felicitas.hitz@kssg.ch	H. Nguyen/ K. Knöpfel
Melanom				
2018-01783	TMB Data Collection	Evaluation of Tumour Mutational Burden in Predicting Sensitivity to Checkpoint Inhibitors in Metastatic Solid Tumours: A Registry Study.	M. Früh Martin.Frueh@kssg.ch	J. Niedermann
2018-01847	ENiGMA	Open label, non-randomized, Phase IB study to characterize safety, tolerability and recommended dose of Tinostamustine (EDO-S101), a first-in-class alkylating histone deacetylase inhibition (HDACi) fusion molecule, in combination with Nivolumab in patients with refractory, locally advanced or metastatic MelAnoma”	M. Jörger Markus.joerger@kssg.ch	Y. Wittwer / K. Knöpfel

STUDIENLISTE September 2019
Studien offen für Accrual
DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

fett = neu

Zuständigkeit
 Arzt/Ärztin
 Clinical Research
 Coordinator (CRC) /
 Studiensekretariat

Myelom				
2018-00820	39/16 OptiPOM	Protocol SAKK 39/16 – OptiPOM Alternate day dosing of Pomalidomide in patients with refractory Multiple Myeloma. A multicenter, single arm phase II trial	T. Silzle Tobias.silzle@kssg.ch	S. Mayr/ J. Niedermann
HNO				
2018-01783	TMB Data Collection	Evaluation of Tumour Mutational Burden in Predicting Sensitivity to Checkpoint Inhibitors in Metastatic Solid Tumours: A Registry Study.	M. Früh Martin.Frueh@kssg.ch	J. Niedermann
Gehirn				
2016-00707 EKSG 16/061	SAKK 67/15 BASILEA	An open-label Phase 1/2a study of BAL101553 administered as intravenous 48-hour infusion in adult patients with advanced solid tumors	M. Jörger Markus.ioerger@kssg.ch	F. Hutter/ K. Knöpfel
2018—00708	EORTC – 1709 BTG	A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide- based radiochemotherapy alone in patients with newly diagnosed glioblastoma	T. Hundsberger Thomas.Hundsberger@kssg.ch	F. Hutter/ J. Niedermann
M A M M A				
Adjuvant				
2018-00838	TAXIS 23/16	SAKK 23/16: Tailored Axillary Surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer. A multicenter randomized phase III trial (TAXIS)	P. Markellou Pagona.Markellou@kssg.ch	T. Zeller/ J. Niedermann
EKSG 14/158	POSITIVE IBCSG 48-14	A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer	S. Riniker Salome.iniker@kssg.ch	R. Demmer/ J. Niedermann
2018-01210	IBCSG - Touch	IBCSG Touch Phase II open label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer	U. Hasler-Strub Ursula.hasler-strub@kssg.ch	R. Demmer/ K. Knöpfel
2018-02210	SAKK 95/17 WISE	A 24 weeks activity program in patients with early breast cancer receiving aromatase inhibitor therapy. A multicenter randomized phase III trial.	S. Riniker Salome.Riniker@kssg.ch	B. Pfister/ K. Knöpfel
2019-0058	SAKK 21/18	Title: Ribociclib-endocrine combination therapy versus chemotherapy as 1st line treatment in patients with visceral metastatic breast cancer. A multicenter, randomized phase III trial.	U. Hasler-Strub Ursula.hasler-strub@kssg.ch	A. Aeschbacher/ K. Knöpfel
Metastasierend				
EKSG 14/057	SAKK 96/12*	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial	A. Omlin Aurelius.Omlin@kssg.ch	H. Nguyen / K. Knöpfel
2016-01006	SAKK 24/14	Anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative EGFR positive breast cancer – A multicenter single arm phase II trial	U. Hasler-Strub Ursula.hasler-strub@kssg.ch	B. Pfister/ J. Niedermann

STUDIENLISTE September 2019
Studien offen für Accrual
DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

fett = neu

Arzt/Ärztin

Zuständigkeit

Clinical Research
 Coordinator (CRC) /
 Studiensekretariat

BLADDER				
2018-00176	SAKK 06/17	Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapie in patients with operable urothelial cancer. A multicentre, single-arm phase II trial.	S. Aeppli Stefanie.Aeppli@kssg.ch	T. Zeller/ J. Niedermann
2018-00151	BAY17403	A randomized, open label, multicenter, seamless Phase 2/3 study to evaluate the efficacy and safety of rogaratinib (BAY 1163877) compared to chemotherapy in patients with FGFRpositive locally advanced or metastatic urothelial carcinoma who have received prior platinum-containing chemotherapy	A. Omlin aurelius.omlin@kssg.ch	F. Hutter/ K. Knöpfel
LUNGE				
PB_2016-00306	MK-3475-091; PEARLS	A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy	M. Früh Martin.frueh@kssg.ch	B. Pfister/ J. Niedermann
2016-01900	SAKK19/16	Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutations: A multicenter phase IB trial.	M. Früh Martin.frueh@kssg.ch	A. Harder/ K. Knöpfel
2018-01254	SAKK 19/17	First line durvalumab in patients with PD-L1 positive, advanced NSCLC with performance status 2 unsuitable for combination chemotherapy. A multicenter, single-arm phase II trial	M. Früh Martin.Frueh@kssg.ch	S. Mayr/ K. Knöpfel
2018-01551	MK3475-495: KeyImPaCT	A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT).	M. Früh Martin.Frueh@kssg.ch	S. Mayr/ J. Niedermann
2018-02355	SAKK 19/18	Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer (SQCLC) overexpressing FGFR mRNA A multicenter, single arm phase II trial	M. Jörger Markus.joerger@kssg.ch	A. Harder/ J. Niedermann
2018 - 02138	ETOP 13-018-meso	A multicentre randomised phase III trial comparing atezolizumab plus bevacizumab and standard chemotherapy versus bevacizumab and standard chemotherapy as first-line treatment for advanced malignant pleural mesothelioma	M. Früh Martin.Frueh@kssg.ch	A. Aeschbacher/ J. Niedermann
KOLON/REKTAL				
EKSG 15/127	SAKK 41/13	Adjuvant aspirin treatment in PIK3CA mutated colon cancer patients. A randomized, double-blinded, placebo-controlled, phase III trial.	U. Güller Ulrich.queller@kssg.ch	J. Kehl/ J. Niedermann
2016-00602	PhenoTox	Hunting the missing heritability of early-onset fluoropyrimidine-related toxicity in cancer patients: an observational multi-center study.	M. Jörger Markus.joerger@kssg.ch	R. Demmer/ J. Niedermann
EKSG 15/156	SAKK 41/14	Protocol SAKK 41/14 ACTIVE-2 Physical activity program in patients with metastatic colorectal cancer who receive palliative first-line chemotherapy. A multicenter open label randomized controlled phase III trial	D. Horber Daniel.horber@kssg.ch	A. Harder/ K. Knöpfel
OESOPHAGEAL				
2016-02105	SAKK PRODIGE 32	Systematic surgery vs monitoring and salvage surgery in operable oesophageal cancer in complete clinical response after chemoradiation Strategic multicenter randomized phase II- III trial	Christian Weisshaupt christian.weisshaupt@kssg.ch	A. Aeschbacher/ K. Knöpfel

STUDIENLISTE September 2019
Studien offen für Accrual
DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

fett = neu

Zuständigkeit
 Arzt/Ärztin
 Clinical Research
 Coordinator (CRC) /
 Studiensekretariat

NIERE				
2017-01595	SAKK 07/17	Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase II trial	Ch. Rothermundt Christian.rothermundt@kssg.ch	H. Nguyen/ J. Niedermann
PROSTATA				
EKSG 14/057	SAKK 96/12*	Prevention of Symptomatic Skeletal Events with Denosumab Administered every 4 Weeks versus every 12 Weeks – A Non-Inferiority Phase III Trial	A. Omlin Aurelius.Omlin@kssg.ch	H. Nguyen/ K. Knöpfel
2016-00127	SAKK 08/14 IMPROVE	Investigation of Metformin in patients with castration resistant prostate cancer in combination with Enzalutamide vs. Enzalutamide alone A randomized, open label, phase II trial	Ch. Rothermundt Christian.rothermundt@kssg.ch	M. Donno/ K. Knöpfel
EKSG 14/155	PRO-PLAT	Single arm open lable phase II pilot study of Carboplatin in patients with metastatic castration-resistant prostate cancer (CRPC) and PTEN-LOSS	A. Omlin Aurelius.omlin@kssg.ch	F. Hutter/ J. Niedermann
2016-01816	SAKK 08/16	ODM-201 maintenance therapy in patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with one novel hormonal agent first line and non-progressive disease after second line treatment with a taxane: A multicenter randomized double-blind placebo-controlled phase II trial	A. Omlin Aurelius.Omlin@kssg.ch	A. Harder/ K. Knöpfel
2019-00235	PEACE-4	A Phase III trial of acetylsalicylic acid and atorvastatin in patients with castrate-resistant prostate cancer, Peace-4	A. Omlin Aurelius.Omlin@kssg.ch	S. Mayr/ K. Knöpfel
HODENKREBS				
EKSG 13/083	SAG TCCS	Prospektive Datenerhebung bei Patienten mit Hodenkrebs	Ch. Rothermundt Christian.rothermundt@kssg.ch	A. Aeschbacher/ J. Niedermann
Urogenital				
2018-01783	TMB Data Collection	Evaluation of Tumour Mutational Burden in Predicting Sensitivity to Checkpoint Inhibitors in Metastatic Solid Tumours: A Registry Study.	M. Früh Martin.Frueh@kssg.ch	J. Niedermann
PHASE I-STUDIEN				
2018-02302	BMS CA027-002	BMS CA027-002: A Phase 1/2 Study of BMS - 986253 in Combination with Nivolumab in Advanced Cancers	M. Jörger Markus.joerger@kssg.ch	P. Caminada J. Niedermann
2016-00707 EKSG 16/061	SAKK 67/15 BASILEA	An open-label Phase 1/2a study of BAL101553 administered as intravenous 48-hour infusion in adult patients with advanced solid tumors	M. Jörger Markus.joerger@kssg.ch	F. Hutter/ K. Knöpfel
2017-00921	MP0274	A phase 1, first-in-human, single-arm, multi-center, open-label, repeated-dose, dose escalation study to assess safety, tolerability, and pharmacokinetics of MP0274 in patients with advanced HER2-positive solid tumors.	A.Omlin Aurelius.omlin@kssg.ch	M. Donno/ J. Niedermann
2017-01310	NIR178	A Phase 2, multi-center, open label study of NIR178 in combination with PDR001 in patients with selected advanced solid tumors and non-Hodgkin lymphoma	M. Joerger Markus.joerger@kssg.ch	P. Caminada/ J. Niedermann
2017-02227 EKSG 17/190	Bayer 18594	An open-label, first-in-human, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and maximum tolerated dose and / or recommended Phase II dose of the ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.	M. Joerger Markus.joerger@kssg.ch	M. Donno/ J. Niedermann

STUDIENLISTE September 2019
Studien offen für Accrual
DIM Onkologie/Hämatologie und Brustzentrum Kantonsspital St. Gallen

fett = neu

Arzt/Ärztin

Zuständigkeit
 Clinical Research
 Coordinator (CRC) /
 Studiensekretariat

2018-00641	SAKK 65/16	TLD-1, a novel Liposomal Doxorubicin, in Patients with Advanced Solid Tumors; a multicenter open-label single-arm phase I trial.	D. Hess dagmar.hess@kssg.ch	A. Harder/ K. Knöpfel
Basec 2015-00091	EDO Phase I EXPANSION	A Phase 1 Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of EDO-S101, a First-in-Class Alkylating Histone Deacetylase Inhibition (HDACi) Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies	Ch Driessen christoph.driessen@kssg.ch	F. Hutter/ K. Knöpfel
Sakrom				
2018-00904	SAKK57/16 NAPAGE	NAb-PAclitaxel and GEmcitabine in advanced soft tissue sarcoma. A multicenter open-label single arm phase Ib/IIa trial.	Ch. Rothermundt Christian.rothermundt@kssg.ch	A. Harder/ J. Niedermann

➔ ➔ ➔ Die Studienliste ist abrufbar auf
<https://www.kssg.ch/onkologie/lehre-forschung/klinische-forschung>

***Diese Studien können grösstenteils auswärts durchgeführt werden.**